Esperion Therapeutics Inc. [NASDAQ: ESPR] loss -3.80% or -0.04 points to close at $0.99 with a heavy trading volume of 4355571 shares. The company report on November 7, 2023 at 6:00 AM that Esperion Reports Third Quarter 2023 Financial Results.
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million –.
– Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 –.
It opened the trading session at $1.05, the shares rose to $1.0698 and dropped to $0.9251, the range by which the price of stock traded the whole day. The daily chart for ESPR points out that the company has recorded -32.13% loss over the past six months. However, it is still -41.43% lower than its most recent low trading price.
If we look at the average trading volume of 3.81M shares, ESPR reached to a volume of 4355571 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Esperion Therapeutics Inc. [ESPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ESPR shares is $8.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ESPR stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Northland Capital have made an estimate for Esperion Therapeutics Inc. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on August 01, 2023.
The Average True Range (ATR) for Esperion Therapeutics Inc. is set at 0.11, with the Price to Sales ratio for ESPR stock in the period of the last 12 months amounting to 1.21.
Trading performance analysis for ESPR stock
Esperion Therapeutics Inc. [ESPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.36. With this latest performance, ESPR shares gained by 7.82% in over the last four-week period, additionally sinking by -32.13% over the last 6 months – not to mention a drop of -88.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ESPR stock in for the last two-week period is set at 54.35, with the RSI for the last a single of trading hit 59.60, and the three-weeks RSI is set at 50.34 for Esperion Therapeutics Inc. [ESPR]. The present Moving Average for the last 50 days of trading for this stock 1.0504, while it was recorded at 0.9782 for the last single week of trading, and 2.1062 for the last 200 days.
Esperion Therapeutics Inc. [ESPR]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Esperion Therapeutics Inc. [ESPR] shares currently have an operating margin of -237.83 and a Gross Margin at +63.61. Esperion Therapeutics Inc.’s Net Margin is presently recorded at -309.58.
Return on Total Capital for ESPR is now -71.65, given the latest momentum, and Return on Invested Capital for the company is -100.88. Additionally, ESPR Total Debt to Total Capital is recorded at 279.11, with Total Debt to Total Assets ending up at 203.50.
Reflecting on the efficiency of the workforce at the company, Esperion Therapeutics Inc. [ESPR] managed to generate an average of -$1,174,166 per employee. Receivables Turnover for the company is 2.66 with a Total Asset Turnover recorded at a value of 0.24.Esperion Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.74 and a Current Ratio set at 2.17.
Esperion Therapeutics Inc. [ESPR]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ESPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Esperion Therapeutics Inc. go to 16.90%.
An analysis of Institutional ownership at Esperion Therapeutics Inc. [ESPR]
The top three institutional holders of ESPR stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in ESPR stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in ESPR stock with ownership which is approximately 5.7994%.